Background/Aims: Oxidative stress has been considered a nontraditional risk factor for cardiovascular disease in the chronic kidney disease (CKD) population, possibly triggered by uremic toxicity. Methods: A chromatographic method with coulometric detection was adapted to directly and simultaneously determine cysteine (Cys) and cystine (Cyss) in plasma samples. Healthy subjects and CKD subjects in different stages were analyzed. The free Cys and free Cyss levels in their plasma were determined, and the reduction potential [Eh(Cyss/2Cys)] was calculated with the Nernst equation. Results: Healthy plasma presented Eh(Cyss/2Cys) of –123 ± 7 mV. Plasma Eh(Cyss/2Cys) correlated significantly with creatinine levels (p < 0.0001, r = 0.62). Conclusion: Plasma Eh(Cyss/2Cys) correlated with increased levels of plasma creatinine, supporting the view that uremia triggers oxidative stress. In addition, it may be used as a quantitative oxidative stress biomarker in uremic conditions.

Keywords:
Oxidative stress, Uremia, Reduction potential, Cysteine, Chronic kidney disease
1.
Luke RG: Chronic renal failure – a vasculopathic state. N Engl J Med 1998;339:841–843.
2.
Ikizler TA: Epidemiology of vascular disease in renal failure. Blood Purif 2002;20:6–10.
3.
Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P: Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 2004;38:405–416.
4.
Halliwell B, Gutteridge JMC: Free Radicals in Biology and Medicine, ed 4. New York, Oxford University Press, 2007.
5.
Himmelfarb J, McMonagle E, McMenamin E: Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000;58:2571–2578.
6.
Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524–1538.
7.
Simmons EM, Langone A, Sezer MT, Vella JP, Recupero P, Morrow JD, Ikizler TA, Himmelfarb J: Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 2005;79:914–919.
8.
Aveles PR, Criminacio CR, Goncalves S, Bignelli AT, Claro LM, Siqueira SS, Nakao LS, Pecoits-Filho R: Association between biomarkers of carbonyl stress with increased systemic inflammatory response in different stages of chronic kidney disease and after renal transplantation. Nephron Clin Pract 2010;116:c294–c299.
9.
Matsuyama Y, Terawaki H, Terada T, Era S: Albumin thiol oxidation and serum protein carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease. Clin Exp Nephrol 2009;13:308–315.
10.
Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304–1313.
11.
Clermont G, Lecour S, Lahet J, Siohan P, Vergely C, Chevet D, Rifle G, Rochette L: Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res 2000;47:618–623.
12.
Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, Blumberg JB: Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001;59:1960–1966.
13.
Himmelfarb J, McMenamin ME, Loseto G, Heinecke JW: Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 2001;31:1163–1169.
14.
Massy ZA, Borderie D, Nguyen-Khoa T, Drueke TB, Ekindjian OG, Lacour B: Increased plasma S-nitrosothiol levels in chronic haemodialysis patients. Nephrol Dial Transplant 2003;18:153–157.
15.
Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK: Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 2003;63:179–185.
16.
Gelasco AK, Raymond JR: Indoxyl sulfate induces complex redox alterations in mesangial cells. Am J Physiol Renal Physiol 2006;290:F1551–F1558.
17.
Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, Brunet P: The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 2007;5:1302–1308.
18.
Jones DP: Redefining oxidative stress. Antioxid Redox Signal 2006;8:1865–1879.
19.
Jones DP: Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 2008;295:C849–C868.
20.
Schafer FQ, Buettner GR: Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001;30:1191–1212.
21.
Jones DP, Carlson JL, Mody VC, Cai J, Lynn MJ, Sternberg P: Redox state of glutathione in human plasma. Free Radic Biol Med 2000;28:625–635.
22.
Jones DP, Mody VC Jr, Carlson JL, Lynn MJ, Sternberg P Jr: Redox analysis of human plasma allows separation of pro-oxidant events of aging from decline in antioxidant defenses. Free Radic Biol Med 2002;33:1290–1300.
23.
Moriarty SE, Shah JH, Lynn M, Jiang S, Openo K, Jones DP, Sternberg P: Oxidation of glutathione and cysteine in human plasma associated with smoking. Free Radic Biol Med 2003;35:1582–1588.
24.
Go YM, Jones DP: Intracellular proatherogenic events and cell adhesion modulated by extracellular thiol/disulfide redox state. Circulation 2005;111:2973–2980.
25.
Iyer SS, Accardi CJ, Ziegler TR, Blanco RA, Ritzenthaler JD, Rojas M, Roman J, Jones DP: Cysteine redox potential determines pro-inflammatory IL-1beta levels. PLoS One 2009;4:e5017.
26.
Ramirez A, Ramadan B, Ritzenthaler JD, Rivera HN, Jones DP, Roman J: Extracellular cysteine/cystine redox potential controls lung fibroblast proliferation and matrix expression through upregulation of transforming growth factor-beta. Am J Physiol Lung Cell Mol Physiol 2007;293:L972–L981.
27.
Jocelyn PC: Chemical reduction of disulfides. Methods Enzymol 1987;143:246–256.
28.
Buege JA, Aust SD: Microsomal lipid peroxidation. Methods Enzymol 1978;52:302–310.
29.
Jones DP, Park Y, Gletsu-Miller N, Liang Y, Yu T, Accardi CJ, Ziegler TR: Dietary sulfur amino acid effects on fasting plasma cysteine/cystine redox potential in humans. Nutrition 2011;27:199–205.
30.
Park Y, Ziegler TR, Gletsu-Miller N, Liang Y, Yu T, Accardi CJ, Jones DP: Postprandial cysteine/cystine redox potential in human plasma varies with meal content of sulfur amino acids. J Nutr 2010;140:760–765.
31.
Melnyk S, Pogribna M, Pogribny I, Hine RJ, James SJ: A new HPLC method for the simultaneous determination of oxidized and reduced plasma aminothiols using coulometric electrochemical detection. J Nutr Biochem 1999;10:490–497.
32.
Petrlova J, Mikelova R, Stejskal K, Kleckerova A, Zitka O, Petrek J, Havel L, Zehnalek J, Vojtech A, Trnkova L, Kizek R: Simultaneous determination of eight biologically active thiol compounds using gradient elution-liquid chromatography with Coul-Array detection. J Sep Sci 2006;29:1166–1173.
33.
Kleinman WA, Richie JP Jr: Status of glutathione and other thiols and disulfides in human plasma. Biochem Pharmacol 2000;60:19–29.
34.
Gaitonde MK: A spectrophotometric method for the direct determination of cysteine in the presence of other naturally occurring amino acids. Biochem J 1967;104:627–633.
35.
Babu CK, Ansari KM, Mehrotra S, Khanna R, Khanna SK, Das M: Alterations in redox potential of glutathione/glutathione disulfide and cysteine/cysteine disulfide couples in plasma of dropsy patients with argemone oil poisoning. Food Chem Toxicol 2008;46:2409–2414.
36.
Wlodek PJ, Smolenski OB, Chwatko G, Iciek MB, Milkowski A, Bald E, Wlodek L: Disruption of thiol homeostasis in plasma of terminal renal failure patients. Clin Chim Acta 2006;366:137–145.
37.
Wlodek PJ, Iciek MB, Milkowski A, Smolenski OB: Various forms of plasma cysteine and its metabolites in patients undergoing hemodialysis. Clin Chim Acta 2001;304:9–18.
38.
Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J: A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008;19:863–870.
39.
Himmelfarb J: Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial 2009;22:636–643.
40.
Niwa T: Uremic toxicity of indoxyl sulfate. Nagoya J Med Sci 2010;72:1–11.
41.
Cendoroglo M, Jaber BL, Balakrishnan VS, Perianayagam M, King AJ, Pereira BJ: Neutrophil apoptosis and dysfunction in uremia. J Am Soc Nephrol 1999;10:93–100.
42.
Galli F, Ghibelli L, Buoncristiani U, Bordoni V, D’Intini V, Benedetti S, Canestrari F, Ronco C, Floridi A: Mononuclear leukocyte apoptosis in haemodialysis patients: the role of cell thiols and vitamin E. Nephrol Dial Transplant 2003;18:1592–1600.
43.
Serradell M, Diaz-Ricart M, Cases A, Zurbano MJ, Lopez-Pedret J, Arranz O, Ordinas A, Escolar G: Uremic medium causes expression, redistribution and shedding of adhesion molecules in cultured endothelial cells. Haematologica 2002;87:1053–1061.
44.
Diaz-Buxo JA, Woods HF: Protecting the endothelium: a new focus for management of chronic kidney disease. Hemodial Int 2006;10:42–48.
45.
Di Marco GS, Hausberg M, Hillebrand U, Rustemeyer P, Wittkowski W, Lang D, Pavenstadt H: Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol 2008;294:F1381–F1387.
46.
Muteliefu G, Enomoto A, Jiang P, Takahashi M, Niwa T: Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. Nephrol Dial Transplant 2009;24:2051–2058.
47.
Stinghen AE, Goncalves SM, Martines EG, Nakao LS, Riella MC, Aita CA, Pecoits-Filho R: Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract 2009;111:c117–c126.
48.
Caimi G, Carollo C, Montana M, Iatrino R, Bondi B, Lo Presti R: Nitric oxide metabolites, leukocyte activation markers and oxidative status in dialyzed subjects. Blood Purif 2009;27:194–198.
49.
Peskin AV, Winterbourn CC: Kinetics of the reactions of hypochlorous acid and amino acid chloramines with thiols, methionine, and ascorbate. Free Radic Biol Med 2001;30:572–579.
50.
Kim HJ, Vaziri ND: Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010;298:F662–F671.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.